Cancer News

FDA Approves Ruxience Biosimlar to Rituxan (07/25/2019)

The FDA approved rituximab-pvvr, a rituximab biosimilar, for use alone or in combination with chemotherapy for the treatment of adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as granulomatosis with polyangiitis and microscopic polyangiitis. This is the second biosimilar to rituximab that has been approved by the FDA. This... Continue Reading

FDA approves lenalidomide for follicular and marginal zone lymphoma (05/30/2019)

On May 28, 2019, the Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). The MAGNIFY clinical trial evaluated 232 patients with relapsed or refractory FL, MZL, or mantle cell lymphoma treated with lenalidomide and rituximab.... Continue Reading

Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma (07/03/2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine if it is intended …

Continue reading "Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma"

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (05/31/2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. About mantle cell lymphoma Mantle …

Continue reading "FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma"

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (05/23/2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.   Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), …

Continue reading "FDA Approves Aliqopa for Relapsed Follicular Lymphoma"

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (05/21/2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Approval was based on a clinical trial in adults …

Continue reading "FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma"

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma (01/23/2018)

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for non-Hodgkin lymphoma. About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its …

Continue reading "Keytruda Effective in Patients with Relapsed or Refractory Lymphoma"

FDA approves Gazyva for previously untreated follicular lymphoma (01/11/2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).1  As previously reported, Gazyva was found …

Continue reading "FDA approves Gazyva for previously untreated follicular lymphoma"

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (12/13/2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL). Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a …

Continue reading "Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma"

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) (11/15/2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer of the skin with no known cure and few new treatment options. It is a disfiguring …

Continue reading "Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)"